1921
Volume 92, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Arachidonic acid (ARA), an omega-6 fatty acid, is a potent schistosomicide that displayed significant and safe therapeutic effects in -infected schoolchildren in low-prevalence regions. We here report on ARA efficacy and safety in treatment of schoolchildren in high-endemicity areas of Kafr El Sheikh, Egypt. The study was registered with ClinicalTrials.gov (NCT02144389). In total, 268 schoolchildren with light, moderate, or heavy infection were assigned to three study arms of 87, 91, and 90 children and received a single dose of 40 mg/kg praziquantel (PZQ), ARA (10 mg/kg per day for 15 days), or PZQ combined with ARA, respectively. The children were examined before and after treatment for stool parasite egg counts and blood biochemical, hematological, and immunological parameters. ARA, like PZQ, induced moderate cure rates (50% and 60%, respectively) in schoolchildren with light infection and modest cure rates (21% and 20%, respectively) in schoolchildren with high infection. PZQ and ARA combined elicited 83% and 78% cure rates in children with light and heavy infection, respectively. Biochemical and immunological profiles were either unchanged or ameliorated after ARA therapy. Combination of PZQ and ARA might be useful for treatment of children with schistosomiasis in high-endemicity regions.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0675
2015-04-01
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/92/4/797.html?itemId=/content/journals/10.4269/ajtmh.14-0675&mimeType=html&fmt=ahah

References

  1. Migliardo F, Tallima H, El Ridi R, , 2014. Is there a sphingomyelin-based hydrogen bond barrier at the mammalian host-schistosome parasite interface? Cell Biochem Biophys 68: 359367.[Crossref]
  2. Migliardo F, Tallima H, El Ridi R, , 2014. Rigidity and resistance of larval- and adult schistosomes-medium interface. Biochem Biophys Res Commun 446: 255260.[Crossref]
  3. Barsoum RS, Esmat G, El-Baz T, , 2013. Human schistosomiasis: clinical perspective: review. J Adv Res 4: 433444.[Crossref]
  4. Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG, , 2010. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis 10: 733736.[Crossref]
  5. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, Naghavi M, Salomon JA, Shibuya K, Vos T, Wikler D, Lopez AD, , 2012. GBD 2010: design, definitions, and metrics. Lancet 380: 20632066.[Crossref]
  6. World Health Organization, 2012. Schistosomiasis: population requiring preventive chemotherapy and number of people treated in 2010. Wkly Epidemiol Rec 87: 3744.
  7. Olliaro PL, Vaillant MT, Belizario VJ, Lwambo NJ, Ouldabdallahi M, Pieri OS, Amarillo ML, Kaatano GM, Diaw M, Domingues AC, Favre TC, Lapujade O, Alves F, Chitsulo L, , 2011. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 5: e1165.[Crossref]
  8. Zwang J, Olliaro PL, , 2014. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-A meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 8: e3286.[Crossref]
  9. Erko B, Degarege A, Tadesse K, Mathiwos A, Legesse M, , 2012. Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, southern Ethiopia. Asian Pac J Trop Biomed 2: 235239.[Crossref]
  10. Black CL, Steinauer ML, Mwinzi PN, Evan Secor W, Karanja DM, Colley DG, , 2009. Impact of intense, longitudinal retreatment with praziquantel on cure rates of Schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop Med Int Health 14: 450457.[Crossref]
  11. Webster BL, Diaw OT, Seye MM, Faye DS, Stothard JR, Sousa-Figueiredo JC, Rollinson D, , 2013. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns. Acta Trop 128: 292302.[Crossref]
  12. Huyse T, Van den Broeck F, Jombart T, Webster BL, Diaw O, Volckaert FA, Balloux F, Rollinson D, Polman K, , 2013. Regular treatments of praziquantel do not impact on the genetic make-up of Schistosoma mansoni in northern Senegal. Infect Genet Evol 18: 100105.[Crossref]
  13. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Tanner M, , 2000. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 5: 771778.[Crossref]
  14. García N, Isturiz G, Aular S, Incani RN, , 2006. The efficacy of human schistosomicide treatment may depend on the rate of transmission. Parasitol Res 98: 545549.[Crossref]
  15. Barakat R, El Morshedy H, , 2011. Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt. Parasitology 138: 440446.[Crossref]
  16. King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG, , 2011. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis 5: e1321.[Crossref]
  17. Wang W, Wang L, Liang YS, , 2012. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 111: 18711877.[Crossref]
  18. El Ridi R, Aboueldahab M, Tallima H, Salah M, Mahana N, Fawzi S, Mohamed SH, Fahmy OM, , 2010. In vitro and in vivo activities of arachidonic acid against Schistosoma mansoni and Schistosoma haematobium . Antimicrob Agents Chemother 54: 33833389.[Crossref]
  19. El Ridi R, Tallima H, Salah M, Aboueldahab M, Fahmy OM, Al-Halbosiy MF, Mahmoud SS, , 2012. Arachidonic acid efficacy and mechanism of action in treatment of hamsters infected with Schistosoma mansoni or S. haematobium . Int J Antimicrob Agents 39: 232239.[Crossref]
  20. El Ridi RAF, Tallima HA-M, , 2013. Novel therapeutic and prevention approaches for schistosomiasis: review. J Adv Res 4: 467478.[Crossref]
  21. El Ridi R, Tallima H, El Ridi R, , 2013. Solving the riddle of the lung-stage schistosomula paved the way to a novel remedy and an efficacious vaccine for schistosomiasis. , ed. Parasitic Diseases—Schistosomiasis. Rijeka, Croatia: InTech, 179202.[Crossref]
  22. Selim S, El Sagheer O, El Amir A, Barakat R, Hadley K, Bruins MJ, El Ridi R, , 2014. Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt. Am J Trop Med Hyg 91: 973981.[Crossref]
  23. Kato K, Miura M, , 1954. Comparative examinations of faecal thick smear techniques with cellophane paper covers. Kisechugaku Zasshi 3: 3537.
  24. Katz N, Chaves A, Pellegrino J, , 1972. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni . Rev Inst Med Trop Sao Paulo 14: 397400.
  25. El Ridi R, Farouk F, Sherif M, Al-Sherbiny M, Osman A, El Gengehi N, Shoemaker CB, , 1998. T and B cell reactivity to a 42-kDa protein is associated with human resistance to both Schistosomiasis mansoni and haematobium . J Infect Dis 177: 13641372.[Crossref]
  26. Barakat R, Farghaly A, el Masry AG, el Sayed MK, Husein MH, Miller FD, , 1995. Schistosoma mansoni in the Nile Delta, Egypt. A large scale epidemiological study in Kafr El Sheikh Governorate. Trop Geogr Med 47: 259265.
  27. Barakat R, el Masry AG, Farghaly A, el Morshidy HN, el Sayed MK, Husein MH, Miller FD, , 1995. Impact of population-based selective chemotherapy on prevalence and intensity of Schistosoma mansoni infections in the Nile Delta: Kafr El Sheikh. Trop Geogr Med 47: 266270.
  28. Barakat R, Farghaly A, Morshidy HN, el Sayed MK, Masry AG, Husein MH, Miller FD, , 1995. Patterns of infection, incidence and reinfection with Schistosoma mansoni in Nile Delta Governorate: Kafr El Sheikh. Trop Geogr Med 47: 270277.
  29. Garba A, Lamine MS, Barkiré N, Djibo A, Sofo B, Gouvras AN, Labbo R, Sebangou H, Webster JP, Fenwick A, Utzinger J, , 2013. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop 128: 334344.[Crossref]
  30. Barakat R, Farghaly A, El Morshedy H, Hassan M, Miller de W, , 1998. Impact of National Schistosomiasis Control Program in Kafr El-Sheikh governorate, Nile Delta, Egypt: an independent evaluation. J Egypt Public Health Assoc 73: 737753.
  31. Greenberg RM, , 2013. New approaches for understanding mechanisms of drug resistance in schistosomes. Parasitology 140: 15341546.[Crossref]
  32. El Ridi R, Tallima H, , 2006. Equilibrium in lung schistosomula sphingomyelin breakdown and biosynthesis allows very small molecules, but not antibody, to access proteins at the host-parasite interface. J Parasitol 92: 730737.[Crossref]
  33. Tallima H, Al-Halbosiy MF, El Ridi R, , 2011. Enzymatic activity and immunolocalization of Schistosoma mansoni and Schistosoma haematobium neutral sphingomyelinase. Mol Biochem Parasitol 178: 2328.[Crossref]
  34. De Clercq D, Vercruysse J, Verle P, Kongs A, Diop M, , 2000. What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections? Trop Med Int Health 5: 744746.[Crossref]
  35. Utzinger J, Keiser J, Shuhua X, Tanner M, Singer BH, , 2003. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 47: 14871495.[Crossref]
  36. Mohamed AA, Mahgoub HM, Magzoub M, Gasim GI, Eldein WN, Ahmed A el A, Adam I, , 2009. Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in eastern Sudan. Trans R Soc Trop Med Hyg 103: 10621064.[Crossref]
  37. Belton O, Fitzgerald DJ, , 2003. The three major pathways involved in arachidonic acid metabolism. Expert Rev Mol Med 5: 7.[Crossref]
  38. Seyberth HW, Oelz O, Kennedy T, Sweetman BJ, Danon A, Frölich JC, Heimberg M, Oates JA, , 1975. Increased arachidonate in lipids after administration to man: effects on prostaglandin biosynthesis. Clin Pharmacol Ther 18: 521529.[Crossref]
  39. Nelson GJ, Schmidt PC, Bartolini G, Kelley DS, Kyle D, , 1997. The effect of dietary arachidonic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 32: 421425.[Crossref]
  40. Roberts MD, Iosia M, Kerksick CM, Taylor LW, Campbell B, Wilborn CD, Harvey T, Cooke M, Rasmussen C, Greenwood M, Wilson R, Jitomir J, Willoughby D, Kreider RB, , 2007. Effects of arachidonic acid supplementation on training adaptations in resistance-trained males. J Int Soc Sports Nutr 4: 21.[Crossref]
  41. Innis SM, Hansen JW, , 1996. Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults. Am J Clin Nutr 64: 159167.
  42. Turner JD, Meurs L, Dool P, Bourke CD, Mbow M, Dièye TN, Mboup S, Polman K, Mountford AP, , 2013. Schistosome infection is associated with enhanced whole-blood IL-10 secretion in response to cercarial excretory/secretory products. Parasite Immunol 35: 147156.[Crossref]
  43. Joseph S, Jones FM, Walter K, Fulford AJ, Kimani G, Mwatha JK, Kamau T, Kariuki HC, Kazibwe F, Tukahebwa E, Kabatereine NB, Ouma JH, Vennervald BJ, Dunne DW, , 2004. Increases in human T helper 2 cytokine responses to Schistosoma mansoni worm and worm-tegument antigens are induced by treatment with praziquantel. J Infect Dis 190: 835842.[Crossref]
  44. Leenstra T, Acosta LP, Wu HW, Langdon GC, Solomon JS, Manalo DL, Su L, Jiz M, Jarilla B, Pablo AO, McGarvey ST, Olveda RM, Friedman JF, Kurtis JD, , 2006. T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum . Infect Immun 74: 370381.[Crossref]
  45. Black CL, Muok EM, Mwinzi PN, Carter JM, Karanja DM, Secor WE, Colley DG, , 2010. Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni . J Infect Dis 202: 399405.[Crossref]
  46. Wilson S, Jones FM, Kenty LC, Mwatha JK, Kimani G, Kariuki HC, Dunne DW, , 2014. Posttreatment changes in cytokines induced by Schistosoma mansoni egg and worm antigens: dissociation of immunity- and morbidity-associated type 2 responses. J Infect Dis 209: 17921800.[Crossref]
  47. Betz M, Fox BS, , 1991. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 146: 108113.
  48. Kelley DS, Taylor PC, Nelson GJ, Schmidt PC, Mackey BE, Kyle D, , 1997. Effects of dietary arachidonic acid on human immune response. Lipids 32: 449456.[Crossref]
  49. Kelley DS, Taylor PC, Nelson GJ, Mackey BE, , 1998. Arachidonic acid supplementation enhances synthesis of eicosanoids without suppressing immune functions in young healthy men. Lipids 33: 125130.[Crossref]
  50. Harbige LS, , 2003. Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. Lipids 38: 323341.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0675
Loading
/content/journals/10.4269/ajtmh.14-0675
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 26 Oct 2014
  • Accepted : 19 Dec 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error